Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma

International Journal of Cancer

Volumn 92, Issue 3, 2001, Pages 441-450

  Gjertsen, Marianne K ^a,d   Buanes, Trond ^a   Rosseland, Arne R ^a   Bakka, Arne ^b   Gladhaug, Ivar ^c   Sreide, Odd ^a   Eriksen, Jon A ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^c STATOIL   (Norway)

^d Mericon   (Norway)

Author keywords

Adenocarcinoma; Granulocyte macrophage colony stimulating factor; Mutant ras; Pancreatic cancer; Peptide vaccination

Indexed keywords

CD4 ANTIGEN; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RAS PEPTIDE VACCINE; RAS PROTEIN; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT VACCINE; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOTOXICITY TEST; DELAYED HYPERSENSITIVITY; DRUG SAFETY; FLOW CYTOMETRY; FOLLOW UP; HUMAN; HUMAN CELL; IMMUNE RESPONSE; NONHUMAN; ONCOGENE K RAS; OUTPATIENT; PANCREAS ADENOCARCINOMA; PRIORITY JOURNAL; RAT; SKIN TEST; T LYMPHOCYTE; TREATMENT OUTCOME; TUMOR BIOPSY; TUMOR DIFFERENTIATION; VACCINATION;

ADENOCARCINOMA; ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; FEMALE; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; HYPERSENSITIVITY, DELAYED; INJECTIONS, INTRADERMAL; LYMPHOCYTES, TUMOR-INFILTRATING; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PEPTIDES; RAS PROTEINS; SURVIVAL RATE; T-LYMPHOCYTES; TREATMENT OUTCOME; VACCINATION;

EID: 0035342594     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/ijc.1205     Document Type: Article

References (28)

1. Pancreatic cancer
2. Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes
3. Frequency and spectrum of mutations at codons 12 and 13 of the c-K-ras gene in human tumors
4. Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln→Leu61)
5. + T cells recognize a peptide corresponding to a common mutation (13Gly→Asp)
6. Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins
7. Overlapping epitopes encompassing a point mutation (12Gly→Arg) in p21 ras can be recognized by HLA-DR, -DP and -DQ restricted T cells
8. Induction of human cytotoxic T cell lines directed against point-mutated p21 ras-derived synthetic peptides
9. + T-cell immunity to mutated ras protein in pancreatic and colon cancer patients
10. Induction and characterization of cytotoxic T lymphocytes recognizing a mutated p21 ras peptide presented by HLA-A *0201
11. Vaccination with mutant ras peptides and induction of T cell responsiveness in pancreatic-carcinoma patients after mutant ras peptide vaccination
12. A phase I vaccine trial with peptides reflecting ras oncogene mutations of solid tumors
13. + T cells from a patient with colon carcinoma, specific for a mutant p21 ras derived peptide (13Gly→Asp), are cytotoxic towards a carcinoma cell line harbouring the same mutation
14. + T lymphocytes, generated by mutant p21-ras (12Val) peptide vaccination of a patient, recognize 12-Val dependent nested epitopes present within the vaccine peptide and kill autologous tumour cells carrying this mutation
15. + T cell lines from patients immunized with ras oncogene-derived peptides reflecting codon 12 mutations
16. The dendritic cell system and its role in immunogenicity
17. Dendritic cells as initiators of tumor immune responses - A possible strategy for tumor immunotherapy?
18. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide-pulsed autologous antigen presenting cells
19. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
20. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
21. Granulocyte-macrophage colony-stimulatory factor: An effective adjuvant for protein and peptide based vaccines
22. Granulocyte-macrophage colony-stimulating factor enhances immune responses to melanoma associated peptides in vivo
23. Generation of immunity to the HER-2/neu oncogenic protein in patients with breast and ovarian cancer using a peptide-based vaccine
24. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin-4 and down-regulated by tumor necrosis factor-alpha
25. K-ras mutations and HLA-DR expression in large bowel adenomas
26. Long-term survival following radical and palliative treatment of patients with carcinoma of the pancreas and papilla of Vater - The prognostic factors influencing the long-term results
27. Ex vivo ras peptide vaccination in patients with advanced pancreatic cancer: Results of a phase I/II study
28. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma